Dr. Julie Louise Gerberding, M.D., M.P.H., has been the Chief Patient Officer of Strategic Communications, Global Public Policy & Population Health and Executive Vice President at Merck & Co., Inc. since July 04, 2016. Dr. Gerberding served as an Executive Vice President of Strategic Communications, Global Public Policy and Population Health at Merck & Co., Inc. from January 2015 to July 4, 2016. Dr. Gerberding served as the President of Merck Vaccines at Merck & Co., Inc. from January 25, 2010 to December 15, 2014. Dr. Gerberding has been an External and Independent Director of Cerner Corporation since March 3, 2017. Dr. Gerberding served as a Director at U.S. Centers For Disease Control And Prevention (CDC) since July 2002 to January 2009. Before becoming CDC Director and Agency for Toxic Substances and Disease Registry (ATSDR) Administrator, Dr. Gerberding served as an Acting Deputy Director of the National Center for Infectious Diseases (NCID), where she played a major role in leading CDC's response to the anthrax bioterrorism events of 2001. She joined CDC in 1998 as Director of the Division of Healthcare Quality Promotion, NCID, where she developed CDC's patient safety initiatives and other programs to prevent infections, antimicrobial resistance and medical errors in healthcare settings. Prior to coming to CDC, Dr. Gerberding was a faculty member at the University of California at San Francisco (UCSF) and directed the Prevention Epicenter, a multidisciplinary research, training and clinical service program that focused on preventing infections in patients and their healthcare providers. Dr. Gerberding is a Clinical Professor of Medicine (Infectious Diseases) at Emory University and an Associate Professor of Medicine (Infectious Diseases) at UCSF. Dr. Gerberding is a member of Phi Beta Kappa, Alpha Omega Alpha (medical honor society), American Society for Clinical Investigation (ASCI), American College of Physicians, Infectious Diseases Society of America, the American Epidemiology Society, the National Academy of Public Administration and the Institute of Medicine. Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. She was named to Forbes Magazine's 100 Most Powerful Women in the world in 2005, 2006, 2007 and 2008 and was named to TIME Magazine's 100 Most Influential People in the World in 2004. She earned a B.A. magna cum laude in Chemistry and Biology and a M.D. at Case Western Reserve University in Cleveland, Ohio. She earned an M.P.H. degree at the University of California, Berkeley in 1990. Dr. Gerberding then completed her Internship and Residency in Internal Medicine at UCSF, where she also served as the Chief Medical Resident before finishing her fellowship in Clinical Pharmacology and Infectious Diseases at UCSF. Dr. Julie Louise Gerberding, M.D., M.P.H., has been the Chief Patient Officer of Strategic Communications, Global Public Policy & Population Health and Executive Vice President at Merck & Co., Inc. since July 04, 2016. Dr. Gerberding served as an Executive Vice President of Strategic Communications, Global Public Policy and Population Health at Merck & Co., Inc. from January 2015 to July 4, 2016. Dr. Gerberding served as the President of Merck Vaccines at Merck & Co., Inc. from January 25, 2010 to December 15, 2014. Dr. Gerberding has been an External and Independent Director of Cerner Corporation since March 3, 2017. Dr. Gerberding served as a Director at U.S. Centers For Disease Control And Prevention (CDC) since July 2002 to January 2009. Before becoming CDC Director and Agency for Toxic Substances and Disease Registry (ATSDR) Administrator, Dr. Gerberding served as an Acting Deputy Director of the National Center for Infectious Diseases (NCID), where she played a major role in leading CDC's response to the anthrax bioterrorism events of 2001. She joined CDC in 1998 as Director of the Division of Healthcare Quality Promotion, NCID, where she developed CDC's patient safety initiatives and other programs to prevent infections, antimicrobial resistance and medical errors in healthcare settings. Prior to coming to CDC, Dr. Gerberding was a faculty member at the University of California at San Francisco (UCSF) and directed the Prevention Epicenter, a multidisciplinary research, training and clinical service program that focused on preventing infections in patients and their healthcare providers. Dr. Gerberding is a Clinical Professor of Medicine (Infectious Diseases) at Emory University and an Associate Professor of Medicine (Infectious Diseases) at UCSF. Dr. Gerberding is a member of Phi Beta Kappa, Alpha Omega Alpha (medical honor society), American Society for Clinical Investigation (ASCI), American College of Physicians, Infectious Diseases Society of America, the American Epidemiology Society, the National Academy of Public Administration and the Institute of Medicine. Dr. Gerberding has received more than 50 awards and honors, including the United States Department of Health and Human Services (DHHS) Distinguished Service Award for her leadership in responses to anthrax bioterrorism and the September 11, 2001 attacks. She was named to Forbes Magazine's 100 Most Powerful Women in the world in 2005, 2006, 2007 and 2008 and was named to TIME Magazine's 100 Most Influential People in the World in 2004. She earned a B.A. magna cum laude in Chemistry and Biology and a M.D. at Case Western Reserve University in Cleveland, Ohio. She earned an M.P.H. degree at the University of California, Berkeley in 1990. Dr. Gerberding then completed her Internship and Residency in Internal Medicine at UCSF, where she also served as the Chief Medical Resident before finishing her fellowship in Clinical Pharmacology and Infectious Diseases at UCSF.

Pathology